Literature DB >> 17658482

Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs.

Mouldy Sioud1, Gro Furset, Lina Cekaite.   

Abstract

Single-stranded (ss) and double-stranded (ds) small interfering RNAs (siRNAs) containing immunostimulatory RNA motifs can activate innate immunity through Toll-like receptor 7/8 (TLR7/8), leading to the production of proinflammatory cytokines and type I interferon. More recently, we have noted that 2'-uridine modified ss or ds siRNAs not only evade immune activation, but can suppress TLR signaling triggered by their unmodified counterparts. Here we compared the inhibitory effects of several 2'-modifications. In contrast to 2'-deoxy uridine modified ss siRNAs, 2'-O-methyl uridine modified ss siRNAs inhibited at nanomolar concentrations the production of TNF-alpha induced by a variety of immunostimulatory RNA sequences. Using oligonucleotide microarrays, we highlight the strong suppressive effect of RNA-containing 2'-O-methyl uridines. Indeed, nearly all of the 270 genes induced by an immunostimulatory ss siRNA were completely inhibited or downregulated by cotreatment with its 2'-O-methyl modified version. Also, 2'-O-methyl modified RNAs inhibited E. coli total RNA or mitochondrial RNA to induce TNF-alpha production in human monocytes. Collectively, these data indicate that 2'-modified RNAs, in particular those containing 2'-O-methyl modification, are recognized with high affinity by TLR7/8, but do not induce downstream signaling. Therefore, this new generation of TLR antagonists can be used as immunosuppressive agents to interfere with TLR signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17658482     DOI: 10.1016/j.bbrc.2007.06.177

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  50 in total

1.  N 6-Methyladenosine modification of hepatitis B and C viral RNAs attenuates host innate immunity via RIG-I signaling.

Authors:  Geon-Woo Kim; Hasan Imam; Mohsin Khan; Aleem Siddiqui
Journal:  J Biol Chem       Date:  2020-07-27       Impact factor: 5.157

Review 2.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

3.  Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses.

Authors:  Sibylle Tluk; Marion Jurk; Alexandra Forsbach; Risini Weeratna; Ulrike Samulowitz; Arthur M Krieg; Stefan Bauer; Jörg Vollmer
Journal:  Int Immunol       Date:  2009-03-30       Impact factor: 4.823

4.  Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects.

Authors:  Chan Il Chang; Jae Wook Yoo; Sun Woo Hong; Shi Eun Lee; Hye Suk Kang; Xiangao Sun; Harry A Rogoff; Changill Ban; Soyoun Kim; Chiang J Li; Dong-Ki Lee
Journal:  Mol Ther       Date:  2009-01-20       Impact factor: 11.454

5.  Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner.

Authors:  Subba Rao Nallagatla; Philip C Bevilacqua
Journal:  RNA       Date:  2008-04-21       Impact factor: 4.942

6.  RNA Interference: Story and Mechanisms.

Authors:  Mouldy Sioud
Journal:  Methods Mol Biol       Date:  2021

7.  Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA.

Authors:  Hayden Peacock; Raymond V Fucini; Prasanna Jayalath; José M Ibarra-Soza; Henry J Haringsma; W Michael Flanagan; Aarron Willingham; Peter A Beal
Journal:  J Am Chem Soc       Date:  2011-06-01       Impact factor: 15.419

8.  Base modification strategies to modulate immune stimulation by an siRNA.

Authors:  Rachel Anne P Valenzuela; Scott R Suter; Alexi A Ball-Jones; José M Ibarra-Soza; Yuxuan Zheng; Peter A Beal
Journal:  Chembiochem       Date:  2014-12-08       Impact factor: 3.164

9.  Dendritic Cells Loaded with Tumor Antigens and a Dual Immunostimulatory and Anti-Interleukin 10-Specific Small Interference RNA Prime T Lymphocytes against Leukemic Cells.

Authors:  Per O Iversen; Elvira Semaeva; Dag R Sorensen; Helge Wiig; Mouldy Sioud
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

10.  Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response.

Authors:  Marie-Elise Bonnet; Patrick Erbacher; Anne-Laure Bolcato-Bellemin
Journal:  Pharm Res       Date:  2008-08-16       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.